{
    "nctId": "NCT01205334",
    "title": "Phase I/II Administration of CMV (Cytomegalovirus)-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B)."
                    },
                    {
                        "type": "variable",
                        "value": "CMV-positive GBM"
                    },
                    {
                        "type": "variable",
                        "value": "CMV seropositive"
                    },
                    {
                        "type": "variable",
                        "value": "Life expectancy 6 weeks or greater"
                    },
                    {
                        "type": "variable",
                        "value": "Karnofsky/Lansky score 50 or greater"
                    },
                    {
                        "type": "variable",
                        "value": "Patient or parent/guardian capable of providing informed consent"
                    },
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Bilirubin less than 1.5x upper limit of normal"
                            },
                            {
                                "type": "variable",
                                "value": "AST less than 3x upper limit of normal"
                            },
                            {
                                "type": "variable",
                                "value": "serum creatinine less than 1.5x normal"
                            },
                            {
                                "type": "variable",
                                "value": "Hgb 8.0 g/dL or greater"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Pulse oximetry of 90% or greater on room air"
                    },
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion"
                            },
                            {
                                "type": "variable",
                                "value": "The male partner should use a condom"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study."
                    },
                    {
                        "type": "variable",
                        "value": "Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent."
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Severe intercurrent infection"
                            },
                            {
                                "type": "variable",
                                "value": "Known HIV positivity"
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or lactating"
                            },
                            {
                                "type": "variable",
                                "value": "History of hypersensitivity reactions to murine protein-containing products"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('AST less than 3x upper limit of normal'), Symbol('Bilirubin less than 1.5x upper limit of normal'), Symbol('CMV seropositive'), Symbol('CMV-positive GBM'), Symbol('Hgb 8.0 g/dL or greater'), Symbol('Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B).'), Symbol('Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.'), Symbol('Karnofsky/Lansky score 50 or greater'), Symbol('Life expectancy 6 weeks or greater'), Symbol('Patient or parent/guardian capable of providing informed consent'), Symbol('Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study.'), Symbol('Pulse oximetry of 90% or greater on room air'), Symbol('Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion'), Symbol('The male partner should use a condom'), Symbol('serum creatinine less than 1.5x normal'), Not(Or(Symbol('History of hypersensitivity reactions to murine protein-containing products'), Symbol('Known HIV positivity'), Symbol('Pregnant or lactating'), Symbol('Severe intercurrent infection'))))"
}